ITGR

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 28, 2002, for Wilson Greatbatch Technologies, Inc. (Note: The request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.). The company is a leading developer and manufacturer of power sources, feedthroughs, and wet tantalum capacitors for implantable medical devices, as well as commercial power sources for aerospace and oil/gas industries.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 16% ($5.3 million) for the quarter and 19% ($12.1 million) for the six months compared to the prior year periods. The Medical segment drove this growth with a 22% quarterly increase, fueled by higher demand for ICD batteries and the inclusion of Greatbatch-Sierra revenues.
• Margin Compression: Gross margin declined to 41% (quarter) and 42% (six months) from 44% and 46% in the prior year. Management attributed this to manufacturing and production yield issues at the Greatbatch-Sierra facility and a decline in royalty revenues from expired patents.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 18% for the quarter, primarily due to Greatbatch-Sierra integration costs, Six Sigma initiatives, and patent activity. Research and development expenses remained relatively flat.
• Amortization Reduction: Intangible amortization decreased significantly (from $1.7 million to $0.9 million for the quarter) due to the cessation of goodwill amortization following the adoption of SFAS No. 142.
• Debt Restructuring Impact: The prior year period included a $3.0 million extraordinary loss on debt retirement, which is absent in the current period, contributing to a higher net income comparison.

Outlook, Risks, and Unusual Items

• Subsequent Acquisition: On July 9, 2002, the company acquired Globe Tool and Manufacturing Company, Inc. for approximately $48 million in cash and $9 million in assumed debt. To fund this, the company amended its credit facility, increasing the total size to $120 million. This acquisition is expected to increase interest expense by approximately 1% and reduce interest income by $0.5 million annually.
• Capital Expenditures: Capital expenditures are expected to increase in 2002 to support expanded production capacity and R&D facility expansions.
• Market Risks: The company faces risks related to dependence on a limited number of customers, product obsolescence, pricing pressure, and reliance on third-party suppliers. A 10% change in short-term interest rates could impact earnings by approximately $0.3 million.
• Accounting Changes: The company plans to adopt SFAS No. 143 (Asset Retirement Obligations) effective December 30, 2002, though no material impact is expected.

Investor Verification Checklist

• Integration of Greatbatch-Sierra: Verify if production yield issues at this acquired facility have been resolved, as they directly impacted gross margins.
• Globe Acquisition Financing: Confirm the terms of the amended $120 million credit facility and the impact of the increased leverage ratio on future interest expenses.
• Medical Segment Demand: Assess the sustainability of the demand increase for ICD batteries and capacitors, which drove the majority of revenue growth.
• Royalty Revenue Decline: Monitor the impact of expired Medtronic patents on future royalty income streams.
• Capital Allocation: Review the company's ability to fund increased capital expenditures and the new acquisition while maintaining liquidity.